-transparent.png){kind=logo}
The level of sCD23 produced in the course of human immunodeficiency virus (HIV) infection was measured in patients grouped according to the Centers for Disease Control by using an immunoradiometric assay. Soluble CD23 was evaluated in supernatants of peripheral blood mononuclear cell (PBMC) (10(6) cells/ml) stimulated by phytohemagglutinin (PHA). Compared with healthy controls (m +/- S.D. = 1.0 +/- 0.34 U/ml, n = 7), higher values were observed in some of the patients of group II (asymptomatic) (m +/- S.D. = 2 +/- 1.33, n = 9) and some of the patients of group IV (AIDS) (m +/- S.D. = 1.3 +/- 1.40, n = 8). Those results prompted us to compare the plasma levels of sCD23 in group II and group IV HIV-infected patients and in healthy individuals. Soluble CD23 plasma levels in healthy patients (n = 42) ranged from 0 to 1.5 U/ml (m +/- S.D. = 0.9 +/- 0.33), in group II patients (n = 17) from 0 to 3 U/ml (m +/- S.D. = 0.92 +/- 0.83) and in group IV patients (n = 73) from 0 to 2.9 U/ml (m +/- S.D. = 1.15 +/- 0.71). The differences between the patients and the healthy individuals were not statistically significant but individual sCD23 values higher than 2 U/ml were obtained in 6% of the group II patients and 16.7% of the group IV patients. Increased values of sCD23 were obtained in plasma from patients with secondary infectious diseases (groups IV-Cl and IV-C2) and from patients without secondary infectious diseases (group II, group IV-A and group IV-B).(ABSTRACT TRUNCATED AT 250 WORDS)
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
July 1993,
The Journal of infectious diseases,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
July 1999,
Journal of virology,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
January 1988,
Nature,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
August 1990,
Ophthalmology,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
July 1999,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
March 1993,
Medicina clinica,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
March 1993,
Medicina clinica,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
November 1995,
Antimicrobial agents and chemotherapy,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
July 1996,
The Journal of infectious diseases,
D Hober, and
F Ajana, and
M Boniface, and
R Estrada, and
P E Lobert, and
C Sartiaux, and
Y Mouton, and
P Wattré, and
M Maniez-Montreuil
January 1994,
International journal of clinical & laboratory research,
